Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT06550076 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06550076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06550076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 4, 2024
Completion date
August 5, 2029
Enrollment
2,099 (actual)
Sites
278

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis